Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Biosimilars: SOP for Scale-Up from Shake Flask to Spinner Flask – V 2.0

Posted on By


Biosimilars: SOP for Scale-Up from Shake Flask to Spinner Flask – V 2.0


Standard Operating Procedure for Scale-Up from Shake Flask to Spinner Flask in Biosimilar Production

Department Biosimilars
SOP No. SOP/BS/066/2025
Supersedes SOP/BS/066/2022
Page No. Page 1 of 12
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To define the procedure for aseptic scale-up of seed cultures from shake flasks to spinner flasks as part of the biosimilar upstream process, maintaining cell viability, sterility, and traceability in accordance with GMP.

2. Scope

This SOP applies to all scale-up operations from shake flasks (125 mL–1 L) to spinner flasks (2 L–5 L) used in biosimilar manufacturing for CHO, HEK293, and other mammalian cell lines.

3. Responsibilities

  • Upstream Technician: Perform inoculation and maintain spinner flask logs.
  • Process Scientist: Monitor growth parameters and determine scale-up readiness.
  • QA Personnel: Review batch documentation and ensure environmental compliance.

4. Accountability

The Upstream Process Manager is accountable for seed culture integrity and ensuring that scale-up activities meet GMP and process development standards.

5. Procedure

5.1 Readiness Assessment

  1. Confirm shake flask culture has VCD ≥ 1.0 × 10⁶ cells/mL and viability ≥ 90%.
  2. Document current culture health in Annexure-1.

5.2 Spinner Flask Setup

  1. Retrieve pre-sterilized spinner flasks (2 L–5 L) with magnetic or paddle stirrers.
  2. Label flask with batch number, media type, date, and flask ID (Annexure-2).
  3. Transfer sterile chemically defined media (CDM) to spinner flask under LAF.

5.3 Aseptic Inoculation

  1. Gently mix shake flask culture and withdraw required volume using sterile pipettes.
  2. Inoculate spinner flask to achieve VCD of ~0.3 × 10⁶ cells/mL.
  3. Secure flask lid and place on magnetic or mechanical stirrer (45–60 rpm) in incubator shaker or CO₂ incubator at 37°C, 5% CO₂.

5.4 Monitoring and Control

  1. Record daily VCD, viability, pH, temperature, and osmolality (Annexure-3).
  2. Perform sterility checks on Day 0 and Day 3 per SOP/BS/043/2025.
  3. Inspect visually for turbidity, sediment, or abnormal morphology.

5.5 Documentation and Review

  1. Update seed train map and transfer batch record to process scientist for review.
  2. QA to verify Annexure entries and approve for bioreactor inoculation.

6. Abbreviations

  • VCD: Viable Cell Density
  • CDM: Chemically Defined Media
  • LAF: Laminar Air Flow
  • GMP: Good Manufacturing Practice

7. Documents

  1. Shake Flask Culture Assessment Sheet – Annexure-1
  2. Spinner Flask Label Log – Annexure-2
  3. Daily Monitoring Log – Annexure-3

8. References

  • ICH Q5D – Cell Substrates for Biotechnological/Biological Products
  • WHO TRS 1010 – Bioprocess Guidelines
  • SOP/BS/043/2025 – Sterility Monitoring

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Shake Flask Culture Assessment Sheet

Date Flask ID VCD (×10⁶/mL) Viability (%) Approved for Scale-Up
03/05/2025 FLK-005 1.2 92 Yes

Annexure-2: Spinner Flask Label Log

Flask ID Volume (L) Media Type Date of Inoculation Operator
SPF-01 2 CD CHO 04/05/2025 Ajay Verma

Annexure-3: Daily Monitoring Log

Date VCD Viability pH Remarks
05/05/2025 0.85 94% 7.1 Healthy Growth

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Included osmolality check and new annexures GMP Audit Requirement
See also  Biosimilars: SOP for Clone Archival and Inventory Management - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: API Manufacturing: SOP for Sample Receipt and Login in QC Lab – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version